Generating solutions

In Canada, the current COVID-19 testing approaches are operating near full capacity, and key reagent supply chains are stressed. Current Public Health testing priority is for symptomatic individuals and close contacts. This is a highly valued and validated standard of care approach but does not readily identify pre or asymptomatic virus spreaders. Due to the highly transmissible nature of the SARS-Cov-2 virus, operational challenges make COVID-19 detection and containment very difficult within the Canadian population. The Chief Medical Officer of Canada has identified an urgent need to ramp up testing capacity for COVID-19, and epidemiologists are strongly recommending expanded testing capacity to inform collective infection control efforts. The overall goal through many mitigations, is to reduce the reproductive rate (R value) of COVID-19 to less than one. Widescale testing, isolation and contract tracing are central to reducing the impact of future waves of COVID-19 disease, at least until an effective vaccine is available. We propose to pilot an innovative protocol that benefits from fewer sample extraction steps and massive scaling potential due to the use of DNA molecular barcodes.